U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
Contact Us FAQs Site Map About MedelinePlus
español
Reuters Health Information Logo

Mammograms may harm young BRCA mutation carriers

Printer-friendly version E-mail this page to a friend

Reuters Health

Tuesday, January 27, 2009

NEW YORK (Reuters Health) - Due to the risk of radiation-induced breast cancer, mammographic screening in young BRCA mutation carriers may have a net harmful effect, according to a report in the Journal of the National Cancer Institute.

Mammographic screening is recommended to begin as early as 25 to 30 years of age in carriers of the BRCA1 or BRCA2 mutation, which increase the risk of developing breast cancer. However, it's not clear what reduction in breast cancer mortality is needed with screening to offset the risks of radiation exposure, Dr. Amy Berrington de Gonzalez, from Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues explain.

Using data from 22 pedigree studies of 8139 subjects, the research team estimates that for BRCA1 mutation carriers, annual mammographic screening starting at 25 to 29 years of age would confer a lifetime risk of radiation-induced breast cancer mortality of 26 per 10,000 women. With annual screening starting from 30 to 34 years and from 35 to 39 years, the risk fell to 20 and 13 per 10,000, respectively.

To overcome these risks, beginning annual screening in the three age groups: 25 to 29 years; 30 to 34 years; and 35 to 39 years old, would need to reduce breast cancer mortality by 51 percent, 12 percent, and 4 percent, respectively, the investigators calculate.

"Estimates were similar for BRCA2 mutation carriers," they report.

Given that mammographic screening is thought to reduce breast cancer mortality by no more than 25 percent in young women, the authors believe that the harms of annual screening would outweigh the benefits in women between 25 and 29 years of age and probably also in those from 30 to 34 years. Only in older women is a net benefit likely to be apparent.

Without actual data, these estimates can be used to guide the decision-making process of weighting the benefits of early mammographic screening against the radiation risks in young women with a BRCA mutation, the authors conclude.

SOURCE: Journal of the National Cancer Institute, February 4, 2009.


Reuters Health

Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Related News:
More News on this Date

Related MedlinePlus Pages: